دیگر

CRISPR درمان: بررسی های اخیر سرمایه تامین مالی

CRISPR Therapeutics: Assessing The Recent Capital Financing

Summary

۵M shares recently issued and expected to close on Jan. 08.

The said capital financing is prudent and strategic to fund their potential breakthrough.

This is an abbreviated version of the in-depth Integrated BioSci Report available in advance to our marketplace subscribers.

The reason why the growth stocks do so much better is that they seem to show gains in value in the hundreds of percent each decade. In contrast, it is an unusual bargain that is as much as 50 percent undervalued. The cumulative effect of this simple arithmetic should be obvious.

– Philip Fisher (the Father of Growth Investing)

On Jan. 05, 2018, the share price of CRISPR Therapeutics (NASDAQ:CRSP), a bioscience focusing on gene-editing and CAR-T to treat serious conditions such as cancers and genetic diseases, continued its rally. The stock added another $2.90 (over 12% profits) to value at $26.81 for the said trading session. Since we recommended the company on Nov. 27, 2017 (just over a month) to subscribers of Integrated BioSci Investing, the stock added another $7.26 (or 37% in capital appreciation). This robust run-up is interesting because, on Jan. 04, 2018, the company announced that the 5M additional common shares issued on Jan. 03 will be priced at $22.75.

Read more

عضویت در کانال زیست فن☑

CRISPR درمان: بررسی های اخیر سرمایه تامین مالی_ اخبار زیست فناوری

Rate this post
برچسب‌ها
نمایش بیشتر

نوشته‌های مشابه

دیدگاهتان را بنویسید

نشانی ایمیل شما منتشر نخواهد شد. بخش‌های موردنیاز علامت‌گذاری شده‌اند *

دکمه بازگشت به بالا
EnglishIran
بستن
بستن